Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines

India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines

Granting data exclusivity for clinical trials would undermine access to medicines

The current model of commercialisation does not work for publicly funded research

Consequences For Access To Medicines